Leukemia & Bleeding: Mechanisms of Platelet Dysfunction, Vascular Abnormalities & Coagulopathy

Bleeding is a hallmark complication of leukemia — particularly acute leukemias (AML, ALL) — driven by multifactorial hemostatic failure.

1. Thrombocytopenia (Platelet Deficiency)

• Marrow infiltration by blasts → ↓ megakaryopoiesis → ↓ platelet production.
• Thresholds: <50k — procedural risk; <20k — spontaneous bleeding risk; <10k — life-threatening hemorrhage.
• Platelet transfusion thresholds: <10k prophylactic; <20k if fever/sepsis; <50k for procedures; <100k for neurosurgery/ocular.

2. Platelet Dysfunction (Qualitative Defects)

• Blast-derived inhibitors (e.g., heparan sulfate-like molecules) impair aggregation.
• Acquired storage pool deficiency (dense granule depletion).
• Dysfunctional glycoprotein receptors (GP Ib/IX/V, GP IIb/IIIa).
• Uremia (if renal involvement) → further platelet dysfunction.

3. Abnormal Vascular Formation & Integrity

• Leukemic infiltration of vessel walls → fragility.
• Angiogenic dysregulation (VEGF, angiopoietins) → abnormal, leaky neovessels.
• Gingival hyperplasia (AML M4/M5) → mucosal bleeding.
• DIC (disseminated intravascular coagulation) — especially APL (AML M3): promyelocytes release tissue factor + procoagulants → simultaneous thrombosis + bleeding.

4. Coagulation Factor Deficiencies

• Liver infiltration → ↓ synthesis of factors II, V, VII, IX, X, fibrinogen.
• Vitamin K deficiency (malnutrition, antibiotics, cholestasis) → ↓ II, VII, IX, X.
• Consumption in DIC.
• Acquired inhibitors (rare: factor VIII, V).

5. Therapy-Related Contributors

• Chemotherapy → thrombocytopenia nadir (days 7–14).
• Anticoagulants (VTE prophylaxis/treatment).
• Antiplatelet agents (rare in this population).
• Asparaginase (ALL) → ↓ fibrinogen, antithrombin, protein C/S.

Clinical Bleeding Patterns

• Petechiae, ecchymoses (thrombocytopenia)
• Mucosal: epistaxis, gingival, menorrhagia, GI, GU
• Retinal, intracranial (catastrophic)
• DIC: simultaneous thrombosis (digital ischemia, organ infarction) + bleeding

Management

• Platelet transfusion (leukoreduced, irradiated, ABO-matched ideal).
• Cryoprecipitate (fibrinogen), FFP (multiple factor deficiencies).
• Tranexamic acid (antifibrinolytic) — caution in DIC/thrombosis risk.
• Treat underlying leukemia — definitive hemostasis restoration.
• APL: ATRA + arsenic trioxide → rapid DIC resolution.

Bleeding in leukemia is a medical emergency requiring hematology/oncology coordination.